Successful treatment of immune-related cystitis by Chai-Ling-Tang (Sairei-To) in a gastric carcinoma patient: Case report and literature review

Wang, Zhiqiang; Zhu, Liping; Huang, Yong; Peng, Ling

doi:10.1016/j.explore.2022.04.002

Cited by 7 publications

(6 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, 12 cases of ICIs associated with cystitis from 11 previous studies were reported (including the current case, Table 1). [1][2][3][4][5][6][7][8][9][10] All the patients came from East Asia (6 from China and 5 from Japan), except 1 from France. Among them, the age ranged from 47 to 78 years old, with 10 males (83.3%).…”

Section: Discussionmentioning

confidence: 99%

Recurrent Cystitis Associated With 2 Programmed Death 1 Inhibitors

Fan,

Zhao,

et al. 2023

Journal of Immunotherapy

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced cancer, however, often with immune-related adverse events (irAEs). Adverse events involving the bladder were extremely rare with only few cases. Herein, we described a rare, recurrent cystitis associated with 2 programmed death 1 inhibitors (pembrolizumab and toripalimab) in 1 patient with advanced liver cancer. Cystitis associated with toripalimab, a novel humanized programmed death 1 monoclonal antibody, was first presented in our case. Cystitis is an extremely rare irAE associated with ICIs, especially anti–programmed death 1 antibodies. With widening indications of ICIs in clinical practice, physicians should be also aware of this rare irAE.

show abstract

Section: Discussionmentioning

confidence: 99%

Recurrent Cystitis Associated With 2 Programmed Death 1 Inhibitors

Fan,

Zhao,

et al. 2023

Journal of Immunotherapy

View full text Add to dashboard Cite

show abstract

“…A 56-year-old man with gastric carcinoma developed immune-related cystitis after five cycles of anti-PD-1 plus paclitaxel and tegafur treatment. The patients recovered without recurrence of their lower urinary tract symptoms after taking the TCM formulation Chai-Ling-Tang orally for 2 months [ 102 ]. Beyond compound formulation, Li et al [ 103 ] reported that acupuncture treatment significantly relieved the symptoms of limb numbness and fatigue in a 63-year-old patient with immune-related Guillain-Barré syndrome (GBS).…”

Section: Tcm In the Treatment And Prevention Of Iraesmentioning

confidence: 99%

Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions

Wang

Liu

et al. 2023

Chin Med

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) have revolutionized cancer management and have been widely applied; however, they still have some limitations in terms of efficacy and toxicity. There are multiple treatment regimens in Traditional Chinese Medicine (TCM) that play active roles in combination with Western medicine in the field of oncology treatment. TCM with ICIs works by regulating the tumor microenvironment and modulating gut microbiota. Through multiple targets and multiple means, TCM enhances the efficacy of ICIs, reverses resistance, and effectively prevents and treats ICI-related adverse events based on basic and clinical studies. However, there have been few conclusions on this topic. This review summarizes the development of TCM in cancer treatment, the mechanisms underlying the combination of TCM and ICIs, existing studies, ongoing trials, and prospects for future development.

show abstract

“…I can also mention the Japanese herbal medicine Sairei-to (TJ-114, or Chai-Ling-Tang in Chinese) used to reduce lower urinary tract symptoms. Sairei-to is made from 12 medicinal herbs including AR [ 24 , 25 ]. There are also composite products based in part on AR, such as Yirui capsules, sold in health food stores, to improve the blood lipid state in patients with hyperlipidemia and to reduce the risk of atherosclerosis [ 26 , 27 ].…”

Section: Tcm Made From Alismatis Rhizomamentioning

confidence: 99%

Pharmacological Properties and Molecular Targets of Alisol Triterpenoids from Alismatis Rhizoma

Bailly

2022

Biomedicines

View full text Add to dashboard Cite

More than 100 protostane triterpenoids have been isolated from the dried rhizomes of Alisma species, designated Alismatis rhizoma (AR), commonly used in Asian traditional medicine to treat inflammatory and vascular diseases. The main products are the alisols, with the lead compounds alisol-A/-B and their acetate derivatives being the most abundant products in the plant and the best-known bioactive products. The pharmacological effects of Ali-A, Ali-A 24-acetate, Ali-B, Ali-B 23-acetate, and derivatives have been analyzed to provide an overview of the medicinal properties, signaling pathways, and molecular targets at the origin of those activities. Diverse protein targets have been proposed for these natural products, including the farnesoid X receptor, soluble epoxide hydrolase, and other enzymes (AMPK, HCE-2) and functional proteins (YAP, LXR) at the origin of the anti-atherosclerosis, anti-inflammatory, antioxidant, anti-fibrotic, and anti-proliferative activities. Activities were classified in two groups. The lipid-lowering and anti-atherosclerosis effects benefit from robust in vitro and in vivo data (group 1). The anticancer effects of alisols have been largely reported, but, essentially, studies using tumor cell lines and solid in vivo data are lacking (group 2). The survey shed light on the pharmacological properties of alisol triterpenoids frequently found in traditional phytomedicines.

show abstract

Successful treatment of immune-related cystitis by Chai-Ling-Tang (Sairei-To) in a gastric carcinoma patient: Case report and literature review

Cited by 7 publications

References 43 publications

Recurrent Cystitis Associated With 2 Programmed Death 1 Inhibitors

Recurrent Cystitis Associated With 2 Programmed Death 1 Inhibitors

Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions

Pharmacological Properties and Molecular Targets of Alisol Triterpenoids from Alismatis Rhizoma

Contact Info

Product

Resources

About